Stocksigma LogoStocksigma Logo

Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth

Fredun Pharmaceuticals is pivoting from OEM manufacturing to a 100% branded portfolio by 2029, targeting doubled revenue and profitability over the next

Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth

Fredun Pharmaceuticals Ltd · Press Release · 08 Oct 2026, 3:03 pm

Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth Fredun Pharmaceuticals is pivoting from OEM manufacturing to a 100% branded portfolio by 2029, targeting doubled revenue and profitability over the next 3–4 years. Key growth drivers include acquiring a 26% stake in Goodman Vetcare at a ₹300 crore valuation, buying pet-wellness brand Furlicks, and developing the WAGR platform. Manufacturing capacity is expanding with a ~40,000 sq. ft. utility block operational by Oct'26 plus 50,000 sq. ft. planned. Capital base increased following a 1.10 crore bonus share allotment on 17th Jul'26 and warrant conversions.

Original exchange filing (PDF)

More announcements from Fredun Pharmaceuticals Ltd

All Fredun Pharmaceuticals Ltd announcements